Trial Profile
Recombinant Activated Factor VII (rFVIIa/ NovoSeven) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemorrhage; Thrombocytopenia
- Focus Therapeutic Use
- 09 Oct 2018 Status changed from recruiting to completed.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 23 Aug 2017 Planned initiation date changed from 17 Aug 2017 to 21 Aug 2017.